Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Pfizer Inc.

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Announces New Chief Business Innovation Officer
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer and BioNTech Announce Collaboration With Brazil’s Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer to Acquire Trillium Therapeutics Inc.
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Prices $1.0 Billion Sustainability Bond
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
U.S. FDA Approves TICOVAC™, Pfizer’s Tick-Borne Encephalitis (TBE) Vaccine
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
PFIZER REPORTS SECOND-QUARTER 2021 RESULTS
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer Provides Update on U.S. FDA Review of Abrocitinib and XELJANZ® Filings
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer and BioNTech Announce Collaboration With Biovac to Manufacture and Distribute COVID-19 Vaccine Doses Within Africa
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer Announces New Investor Relations Leader
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Declares Third-Quarter 2021 Dividend
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combination Study of Talazoparib and Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Data Published in New England Journal of Medicine Shows Pfizer’s Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to View and Listen to Webcast of Pfizer July 28 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Initiates Study Exploring Coadministration of Its 20-valent Pneumococcal Conjugate Vaccine Candidate Along With a Third Dose of the Pfizer-BioNTech COVID-19 Vaccine in Older Adults
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer and BioNTech to Supply the European Union With up to 1.8 Billion Additional Doses of COMIRNATY®
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of Their COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer and BioNTech to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2020 Tokyo Games
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.